CSPC Selected as China's Top 10 Innovative BigPharma Companies

On September 16, 2022, Menet held an online launch event for its "Innovation Leads Future-2021 China's Top 100 Innovative Biopharma Companies" list. CSPC was selected as one of China's Top 10 Innovative BigPharma Companies, among the top three.

For the annual "China's Top 100 Innovative Biopharma Companies" list, Menet has identified 11 indicators in four dimensions for innovation capability under the guidance of Enterprise Innovation Capability Evaluation Index System constructed by the Ministry of Science and Technology, which covers innovation investment, innovation achievement, intellectual property and innovation momentum. Menet conducts a comprehensive assessment of innovative pharmaceutical companies based on their annual reports, CDE reviews, third-party patent statistics and public data.

Companies shortlisted for the BigPharma list are required to meet three conditions. First, they must offer more than 10,000 jobs; second, they must invest more than RMB 1 billion in R&D in 2021; and third, they must have Class 1 innovative drugs in Phase II clinical trials or above in 2021.

CSPC remains one of the top three in China's Top 10 Innovative BigPharma Companies.

Over more than 20 years of development, CSPC has grown into a national-level innovative company specializing in pharmaceutical R&D, manufacturing and sales, with a workforce of nearly 30,000 employees, including more than 2,000 researchers. The Group has not only provided a large number of jobs but also has become a hub for top talents, playing a leading and pioneering role in the high-quality development of the domestic pharmaceutical industry.

In 2021, CSPC invested RMB 3.5 billion in R&D, maintaining a high growth rate. At present, the Group has about 300 projects under research, including more than 40 micromolecule drugs, over 40 macromolecule drugs and about 30 innovative preparations, focusing on the treatment of cancer, immune and respiratory diseases, psychiatric and neurological diseases, metabolic diseases, cardiovascular and cerebrovascular diseases and infectious diseases.

CSPC's pipeline of products under development includes several Class 1 innovative drugs with major products containing great market potential.